Medigen Biotechnology Corp. (TPEX: 3176)
Taiwan
· Delayed Price · Currency is TWD 35.80
+0.10 (0.28%)
Sep 11, 2024, 11:26 AM CST
Medigen Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -433.07 | -561.3 | -675.87 | -52.61 | -337.92 | -255.72 |
| Depreciation & Amortization | 172.78 | 175.77 | 189.13 | 196.35 | 217 | 210.59 |
| Other Amortization | 29.24 | 32.87 | 21.87 | 2.08 | 1.84 | 2.86 |
| Loss (Gain) From Sale of Assets | -98.37 | 1.03 | - | 0.25 | -19.95 | -154.85 |
| Asset Writedown & Restructuring Costs | - | - | - | - | - | 109.61 |
| Loss (Gain) From Sale of Investments | 7.8 | 9.58 | 16.66 | -10.92 | 2.42 | -0.43 |
| Loss (Gain) on Equity Investments | 69.46 | 92.26 | 262.21 | 98.8 | 54.57 | 58.24 |
| Stock-Based Compensation | 5.67 | 22.37 | 82.07 | 77.4 | 54.87 | 39.8 |
| Provision & Write-off of Bad Debts | 19 | 14.44 | 21.13 | -20.49 | -3.17 | -91.21 |
| Other Operating Activities | -342.35 | -800.48 | -1,220 | 1,181 | -545.47 | -433.52 |
| Change in Accounts Receivable | -206.29 | 43.35 | 443.69 | -650.83 | 22.77 | -92.63 |
| Change in Inventory | 400.01 | 145.92 | 60.29 | -429.02 | -187.54 | -4.51 |
| Change in Accounts Payable | -18.38 | -74.37 | 30.8 | 53.83 | 39.09 | -0.03 |
| Change in Unearned Revenue | 89.92 | 4.6 | -114.03 | 130.5 | 11.78 | 16.21 |
| Change in Other Net Operating Assets | 67 | 336.49 | -255.21 | -58.37 | -18.49 | 74.86 |
| Operating Cash Flow | -183.1 | -503.52 | -1,138 | 518.12 | -687.6 | -557.6 |
| Capital Expenditures | -37.85 | -38.41 | -148.16 | -142.96 | -132.64 | -110.44 |
| Sale of Property, Plant & Equipment | 0.17 | - | - | 126 | 24.65 | 0.58 |
| Divestitures | - | - | - | - | - | 6.86 |
| Sale (Purchase) of Intangibles | -3.1 | -3.49 | -3.21 | -1.59 | -7.65 | -1.39 |
| Investment in Securities | 2,093 | 492.47 | -2,297 | -879.7 | -104.49 | 565.88 |
| Other Investing Activities | 197.59 | 47.09 | -4.54 | -12.25 | -16.95 | -14.95 |
| Investing Cash Flow | 2,250 | 497.66 | -2,453 | -910.5 | -237.09 | 446.53 |
| Short-Term Debt Issued | - | 210 | 308 | 370 | 412 | 315 |
| Long-Term Debt Issued | - | 29.7 | 1,755 | - | 10 | - |
| Total Debt Issued | 158.7 | 239.7 | 2,063 | 370 | 422 | 315 |
| Short-Term Debt Repaid | - | -135.4 | -280 | -545 | -312 | -225 |
| Long-Term Debt Repaid | - | -28.23 | -28.91 | -22.49 | -471.82 | -127.86 |
| Total Debt Repaid | -2,037 | -163.63 | -308.91 | -567.49 | -783.82 | -352.86 |
| Net Debt Issued (Repaid) | -1,879 | 76.07 | 1,754 | -197.49 | -361.82 | -37.86 |
| Issuance of Common Stock | 3.29 | 3.29 | 2.41 | 11.27 | 4.45 | - |
| Repurchase of Common Stock | -12.39 | -18.59 | - | - | - | - |
| Other Financing Activities | 210.13 | 132.39 | 1,734 | 517.57 | 2,669 | 401.61 |
| Financing Cash Flow | -1,678 | 193.15 | 3,490 | 331.35 | 2,311 | 363.75 |
| Foreign Exchange Rate Adjustments | 10.19 | -5 | -3.08 | -0.96 | 6.34 | -7.54 |
| Net Cash Flow | 399.05 | 182.29 | -103.95 | -62 | 1,393 | 245.14 |
| Free Cash Flow | -220.95 | -541.93 | -1,286 | 375.16 | -820.23 | -668.04 |
| Free Cash Flow Margin | -15.86% | -46.81% | -121.82% | 9.57% | -133.25% | -120.95% |
| Free Cash Flow Per Share | -1.59 | -3.89 | -9.25 | 2.70 | -5.90 | -4.82 |
| Cash Interest Paid | 26.63 | 25.61 | 20.1 | 19.07 | 31.88 | 31.63 |
| Cash Income Tax Paid | 52.88 | 40.23 | 23.35 | 8.37 | 0.36 | 9.52 |
| Levered Free Cash Flow | 78.57 | -190.22 | -660.21 | -246.5 | -820.31 | -168.94 |
| Unlevered Free Cash Flow | 85.35 | -185.56 | -654.91 | -234.58 | -800.38 | -149.17 |
| Change in Net Working Capital | -449.35 | -426.28 | -264.61 | 853.33 | 363.61 | -185.88 |
Source: S&P Capital IQ. Standard template. Financial Sources.